Home › Companies › 10X GENOMICS INC. › 2024-2025

10X GENOMICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and 10X GENOMICS INC.’s Form 8-K, filed 2025-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Ballot items
282Asset managers
1,185Fund votes
2025-06-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore 10X GENOMICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by 10X GENOMICS INC.

These tallies are 10X GENOMICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

10X GENOMICS INC. — official shareholder meeting results, meeting held 2025-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Sri Kosaraju	189,313,724	7,243,542	172,526	--	19,837,766	Majority: yes
Elect Director: Shehnaaz Suliman	168,973,468	27,595,026	161,298	--	19,837,766	Majority: yes
Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year	215,766,816	312,396	488,346	--	--	Majority: yes
Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as descr	164,321,765	32,192,042	215,985	--	19,837,766	Majority: yes

Source: 10X GENOMICS INC., Form 8-K, filed with the SEC on 2025-06-05 — read the filing on EDGAR.

How asset managers voted at the 10X GENOMICS INC. 2024-2025 meeting

Each item below shows how the 282 asset managers that disclosed a 10X GENOMICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 13 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%AGAINST 16%

FOR: 164,321,765AGAINST: 32,192,042

10X GENOMICS INC.’s own tally for this item (“Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executi”): 164,321,765 for, 32,192,042 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 277 asset managers below cast 63% of the shares they voted on this item FOR (53,324,062 for, 31,452,373 against).

FOR 63%AGAINST 37%

FOR: 53,324,062 (62.8%)AGAINST: 31,452,373 (37.0%)ABSTAIN: 90,016 (0.1%)NOT VOTED: 50,939 (0.1%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at 10X GENOMICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	22,921,699	53,636	For
ARK ETF Trust	11,685,143	0	For
Vanguard	11,374,579	16,600	For
Nikko Asset Management Co., Ltd.	0	5,389,611	Against
BlackRock	684,474	4,210,981	Against
Capital Group	0	2,904,600	Against
Two Sigma	0	2,159,053	Against
UBS	0	2,111,528	Against
GEODE CAPITAL MANAGEMENT, LLC	1,962,561	0	For
RA CAPITAL MANAGEMENT, L.P.	0	1,655,103	Against
DEERFIELD MANAGEMENT COMPANY, L.P.	1,505,585	0	For
State Street	1,406,692	47,580	For
Charles Schwab	0	1,306,256	Against
Camber Capital Management LP	0	1,000,000	Against
JACOBS LEVY EQUITY MANAGEMENT, INC	0	751,273	Against
AQR	0	601,164	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	525,945	Against
Sands Capital Alternatives, LLC	0	481,770	Against
BOSTON MANAGEMENT & RESEARCH	0	467,079	Against
MARSHALL WACE, LLP	0	439,403	Against
STATE OF MICHIGAN RETIREMENT SYSTEM	0	399,413	Against
T. Rowe Price	0	371,894	Against
Morgan Stanley	0	356,782	Against
ARK Investment Management LLC	356,669	0	For
Amundi	0	320,340	Against

Showing the 25 largest of 277 asset managers. See all 277 in the interactive database.

2. Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director's successors are duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Shehnaaz Suliman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 5 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST 14%

FOR: 168,973,468AGAINST: 27,595,026

10X GENOMICS INC.’s own tally for this item (“Elect Director: Shehnaaz Suliman”): 168,973,468 for, 27,595,026 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 59 asset managers below cast 92% of the shares they voted on this item FOR (37,993,917 for, 3,482,903 against).

FOR 92%8%

FOR: 37,993,917 (91.6%)AGAINST: 3,482,903 (8.4%)ABSTAIN: 5,725 (0.0%)

Largest asset managers voting on “Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of st” at 10X GENOMICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	10,468,494	1,745,533	For
ARK ETF Trust	11,685,143	0	For
Vanguard	11,146,941	921	For
BlackRock	2,235,570	0	For
Capital Group	1,452,300	0	For
Charles Schwab	0	652,941	Against
AMERICAN BEACON FUNDS	256,431	0	For
TIAA	0	193,983	Against
Columbia Threadneedle	128,546	0	For
Global X	0	123,044	Against
Exchange Place Advisors Trust	0	120,562	Against
ARK Venture Fund	96,720	0	For
Voya	0	95,424	Against
Morgan Stanley	82,018	0	For
Equitable	55,370	26,354	For
Pacific Life	81,614	0	For
NORTHERN LIGHTS FUND TRUST III	78,523	0	For
MASTER INVESTMENT PORTFOLIO	77,014	0	For
Lincoln Financial	3,416	63,860	Against
Nationwide	0	55,973	Against
SEI	0	50,514	Against
Invesco	0	50,328	Against
PACE SELECT ADVISORS TRUST	0	46,308	Against
T. Rowe Price	46,201	0	For
ALGER FUNDS	0	38,365	Against

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

3. Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director's successors are duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Sri Kosaraju

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 189,313,724AGAINST: 7,243,542

10X GENOMICS INC.’s own tally for this item (“Elect Director: Sri Kosaraju”): 189,313,724 for, 7,243,542 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 59 asset managers below cast 99.6% of the shares they voted on this item FOR (41,311,794 for, 165,026 against).

FOR 99.5%

FOR: 41,311,794 (99.6%)AGAINST: 165,026 (0.4%)ABSTAIN: 5,725 (0.0%)

Largest asset managers voting on “Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of st” at 10X GENOMICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	12,214,027	0	For
ARK ETF Trust	11,685,143	0	For
Vanguard	11,146,942	920	For
BlackRock	2,235,570	0	For
Capital Group	1,452,300	0	For
Charles Schwab	652,941	0	For
AMERICAN BEACON FUNDS	256,431	0	For
TIAA	193,983	0	For
Columbia Threadneedle	128,546	0	For
Global X	123,044	0	For
Exchange Place Advisors Trust	120,562	0	For
ARK Venture Fund	96,720	0	For
Voya	0	95,424	Against
Morgan Stanley	82,018	0	For
Equitable	55,370	26,354	For
Pacific Life	81,614	0	For
NORTHERN LIGHTS FUND TRUST III	78,523	0	For
MASTER INVESTMENT PORTFOLIO	77,014	0	For
Lincoln Financial	64,105	3,171	For
Nationwide	55,973	0	For
SEI	50,514	0	For
Invesco	50,328	0	For
PACE SELECT ADVISORS TRUST	46,308	0	For
T. Rowe Price	46,201	0	For
ALGER FUNDS	38,365	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

4. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 215,766,816AGAINST: 312,396

10X GENOMICS INC.’s own tally for this item (“Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the C”): 215,766,816 for, 312,396 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 59 asset managers below cast 99.8% of the shares they voted on this item FOR (41,397,442 for, 79,378 against).

FOR 99.7%

FOR: 41,397,442 (99.8%)AGAINST: 79,378 (0.2%)ABSTAIN: 5,725 (0.0%)

Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at 10X GENOMICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	12,214,027	0	For
ARK ETF Trust	11,685,143	0	For
Vanguard	11,147,862	0	For
BlackRock	2,235,570	0	For
Capital Group	1,452,300	0	For
Charles Schwab	652,941	0	For
AMERICAN BEACON FUNDS	256,431	0	For
TIAA	193,983	0	For
Columbia Threadneedle	128,546	0	For
Global X	123,044	0	For
Exchange Place Advisors Trust	120,562	0	For
ARK Venture Fund	96,720	0	For
Voya	95,424	0	For
Morgan Stanley	82,018	0	For
Equitable	81,724	0	For
Pacific Life	81,614	0	For
NORTHERN LIGHTS FUND TRUST III	0	78,523	Against
MASTER INVESTMENT PORTFOLIO	77,014	0	For
Lincoln Financial	67,276	0	For
Nationwide	55,973	0	For
SEI	50,514	0	For
Invesco	50,328	0	For
PACE SELECT ADVISORS TRUST	46,308	0	For
T. Rowe Price	46,201	0	For
ALGER FUNDS	38,365	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

5. A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-06-11 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%

FOR: 180,775,070AGAINST: 36,417,839

10X GENOMICS INC.’s own tally for this item (“Proposal 4 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executi”): 180,775,070 for, 36,417,839 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 3 asset managers below cast 20% of the shares they voted on this item FOR (127 for, 517 against).

FOR 20%AGAINST 80%

FOR: 127 (19.7%)AGAINST: 517 (80.3%)

Largest asset managers voting on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers” at 10X GENOMICS INC., 2024-2025
Asset manager	For	Against	Vote
COLDSTREAM CAPITAL MANAGEMENT INC	0	517	Against
St. Louis Trust Co	127	0	For
Echo45 Advisors LLC	0	0	--

Largest 10X GENOMICS INC. shareholders voting in 2024-2025

Ranked by the number of 10X GENOMICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 122,291,837 shares outstanding at the time of that meeting.

Top 10X GENOMICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	18.79%
2	ARK ETF Trust	9.56%
3	Vanguard	9.31%
4	Nikko Asset Management Co., Ltd.	4.41%
5	BlackRock	4.00%
6	Capital Group	2.38%
7	Two Sigma	1.77%
8	UBS	1.73%
9	GEODE CAPITAL MANAGEMENT, LLC	1.60%
10	RA CAPITAL MANAGEMENT, L.P.	1.35%

Reported 10X GENOMICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

10X GENOMICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
ARK Investment Management LLC	9.72%	13G
Vanguard Group	9.09%	13F
FMR (Fidelity)	8.09%	13F
Vanguard Portfolio Management	5.71%	13G
BlackRock	5.45%	13F
Nikko Asset Management Americas, Inc.	4.91%	13G
Sumitomo Mitsui Trust Group, Inc.	4.40%	13G
Millennium Management	4.40%	13F
Amova Asset Management Americas, Inc.	4.40%	13G
Morgan Stanley	2.27%	13F

Percentages above are of 122,291,837 shares outstanding, as reported by 10X GENOMICS INC. on its Form 10-K dated 2024-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10X GENOMICS INC.’s 10-K dated 2024-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At 10X GENOMICS INC.'s shareholder meeting held 2025-06-03, in the 2024-2025 proxy season, 282 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,185 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — FOR was 84% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: 10X GENOMICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-05.

10X GENOMICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.